(MENAFN- GlobeNewsWire – Nasdaq) SAN DIEGO, Feb. 2, 2024 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (“the Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to delivering on the promise of precision medicines for the treatment of cancer, today announced that on February 1, 2024, the pay committee of the Company’s board of directors (the “Compensation Committee”) awarded incentives consisting of non-statutory inventory features to acquire 59,750 non-unusual inventories. inventory to 3 (3) new workers under the Company’s 2023 Incentive Option Plan. The Compensation Committee approved the inventory characteristics as a significant incentive to employ those workers, in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has a percentage restructuring value equal to $21. 02 per percent, the Company’s final sale value on February 1, 2024, and will be granted for four years, with 25% of the underlying based on percentages acquired on the first anniversary. of the applicable inventory option. And the balance of the underlying asset in accordance with the percentages will be granted according to the following month for 36 months, subject to the continued service of the new employees with the Company until the applicable vesting dates. The characteristics of the shares are subject to the terms and situations of the Company’s 2023 Incentive Option Plan and the terms and situations of an applicable inventory option agreement covering the grant.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to understanding the promise of precision medicines for the treatment of cancer. The company’s pipeline is comprised of small molecule drug applicants that target cancer signaling pathways. Ziftomenib is a once-daily oral drug candidate that targets the menin-KMT2A protein-protein interaction for the treatment of patients with genetically explained acute myeloid leukemia (AML) with high unmet need. Kura is currently enrolling patients in a registry-based Phase 2 trial of ziftomenib in relapsed or refractory NPM1-mutant acute myeloid leukemia (KOMET-001). The Company is also conducting a series of studies to compare ziftomenib in combination with existing criteria of care, starting with venetoclax and azacitidine and 7+3 in newly diagnosed and relapsed/refractory KMT2A and NPM1 rearranged mutant AML (KOMET- 007). Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in admixture with alpelisib in patients with mobile squamous cell carcinoma of the head and neck. PIK3CA-dependent neck (KURRENT-HN). Kura is also comparing KO-2806, a next-generation FTI, in a phase 1 dose-escalation trial as monotherapy and in admixture with cabozantinib in clear mobile renal cell carcinoma and adagrasib in non-small lung cancer. mutated mobiles via KRASG12C (FIT -001). For more information, visit Kura’s online page at and stay with us on X and LinkedIn.
Contacts
Investors:Pete De SpainExecutive Vice President, Investor Relations &Corporate Communications(858) 500-8833…
Media: Alexandra Weingarten Associate Director, Corporate Communications & Investor Relations (858) 500-8822. . .
MENAFN02022024004107003653ID1107802104
Keywords
comment
Category
Date